Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorPons Delgado, Mònica
dc.contributor.authorRivera Esteban, Jesus Manuel
dc.contributor.authorManzano Nuñez, Ramiro
dc.contributor.authorBañares Sanchez, Juan
dc.contributor.authorBermúdez Ramos, María
dc.contributor.authorVargas Blasco, Victor Manuel
dc.contributor.authorSalcedo Allende, Maria Teresa
dc.contributor.authorCastells Fusté, Lluis
dc.contributor.authorAugustin Recio, Salvador
dc.contributor.authorMinguez Rosique, Beatriz
dc.contributor.authorPericàs Pulido, Juan Manuel
dc.date.accessioned2022-09-07T11:45:21Z
dc.date.available2022-09-07T11:45:21Z
dc.date.issued2022-05
dc.identifier.citationPons M, Rivera-Esteban J, Manzano R, Bañares J, Bermúdez M, Vargas V, et al. Non-Invasive Tests of Liver Fibrosis Help in Predicting the Development of Hepatocellular Carcinoma among Patients with NAFLD. J Clin Med. 2022 May;11(9):2466.
dc.identifier.issn2077-0383
dc.identifier.urihttp://hdl.handle.net/11351/8050
dc.descriptionHepatocellular carcinoma; Transient elastography
dc.description.abstractBackground: The potential role of non-invasive tests (NITs) for liver fibrosis for hepatocellular carcinoma (HCC) prediction remains poorly known. Methods: Retrospective analysis of a NAFLD cohort from a single university hospital in Barcelona, Spain. Incidence rates and cumulative incidence for the overall cohort, as well as cirrhotic and non-cirrhotic patients were calculated. Logistic regression analyses were carried out to investigate risk factors of HCC. Results: From the entire cohort of 1040 patients, 996 patients (95.8%) were analyzed, in whom 35 cases of HCC were detected, of which 26 (72.4%) HCC incident cases were newly diagnosed during a median follow-up of 2.5 (1.9–3.6) years. Two-hundred and thirty-one (23.2%) were cirrhotic at baseline. With the exception of 2 (7.7%) cases of HCC, the rest were diagnosed in cirrhotic patients. Overall HCC cumulative incidence was 9.49 (95% CI 6.4–13.9) per 1000 person-years. The incidence rate for cirrhotic patients was 41.2 (95% CI 27.6–61.6) per 1000 person-years and 0.93 (95% CI 0.23–3.7) per 1000 person-years for patients without cirrhosis. Overall mortality was significantly higher amongst patients with HCC (4.4% vs. 30.8%, p < 0.001). In patients with available liver biopsy (n = 249, 25%), advanced fibrosis (F3–F4) was significantly associated with higher HCC incidence, but not steatosis, lobular inflammation, nor ballooning. In the overall cohort, FIB-4 ≥1.3 (HR 8.46, 95% CI 1.06–67.4, p = 0.044) and older age (HR 1.06, 95% CI 1.01–1.11, p = 0.025) were associated with increasing risk of HCC over time, whereas in cirrhotic patients predictors of HCC included decreasing values of albumin (HR 0.34, 95% CI 0.13–0.87, p = 0.024), platelets (HR 0.98, 95% CI 0.98–0.99, p = 0.001), and increasing values of liver stiffness (HR 1.03, 95% CI 1.00–1.06, p = 0.016). Conclusions: In a Spanish cohort of NAFLD patients, HCC was rare in non-cirrhotic patients. NITs might play a relevant role at predicting HCC.
dc.language.isoeng
dc.publisherMDPI
dc.relation.ispartofseriesJournal of Clinical Medicine;11(9)
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceScientia
dc.subjectCirrosi hepàtica
dc.subjectFetge - Càncer - Diagnòstic
dc.subjectEsteatosi hepàtica
dc.subject.meshCarcinoma, Hepatocellular
dc.subject.mesh/diagnosis
dc.subject.meshNon-alcoholic Fatty Liver Disease
dc.subject.meshLiver Cirrhosis
dc.titleNon-Invasive Tests of Liver Fibrosis Help in Predicting the Development of Hepatocellular Carcinoma among Patients with NAFLD
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.3390/jcm11092466
dc.subject.decscarcinoma hepatocelular
dc.subject.decs/diagnóstico
dc.subject.decsesteatosis hepática no alcohólica
dc.subject.decscirrosis hepática
dc.relation.publishversionhttps://doi.org/10.3390/jcm11092466
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Pons M, Manzano R, Bañares J, Bermúdez M] Servei d’Hepatologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. [Rivera-Esteban J] Servei d’Hepatologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Facultat de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. [Vargas V, Castells L, Mínguez B] Servei d’Hepatologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Facultat de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. Centro de Investigación Biomédica en Red de Enfermedades Digestivas y Hepáticas (CIBERehd), 28029 Madrid, Spain. [Salcedo-Allende MT] Facultat de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. Servei de Patologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Augustin S, Pericàs JM] Servei d’Hepatologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Centro de Investigación Biomédica en Red de Enfermedades Digestivas y Hepáticas (CIBERehd), 28029 Madrid, Spain
dc.identifier.pmid35566592
dc.identifier.wos000796146700001
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record